date:Apr 15, 2014
The US Food and Drug Administration is today announcing that five drug sponsors holding animal drug applications affected by Guidance For Industry (GFI) #213 have requested that FDA withdraw approval of a collective 19 animal drug applications because the products are no longer manufactured or marketed.
Of these 19 applications, 16 are antimicrobials affected by GFI #213. The guidance outlines FDAs plan to help curb antimicrobial resistance by, among other things, phasing out the use of medical